TERN Terns Pharmaceuticals

Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

FOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that members of management will be participating in a fireside chat at the JMP Securities Hematology and Oncology Summit. Details are as follows:

JMP Securities Hematology and Oncology Summit

Fireside Chat Date/Time: Wednesday, December 6, 2023 at 12:30 PM ET

Location: Virtual

A live webcast of the Fireside Chat will be available on the investor relations page of the Terns Pharmaceuticals website at . A replay of the webcast will be archived on Terns’ website for at least 30 days following the presentation.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns’ pipeline includes three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator program. For more information, please visit: .

Contacts for Terns

Investors

Justin Ng

 

Media

Jenna Urban

Berry & Company Public Relations

 



EN
29/11/2023

Underlying

TERNTerns Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Terns Pharmaceuticals

 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Announces Abstract with Positive Clinical Data for TERN-701 in R...

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on December 8th at 4:30pm ET FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical stage oncology company, today announced that data from the ongo...

7h / 3m 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Tr...

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during post-treatment follow-up period, two of which were deemed drug related Company will not advance TERN-601 or invest in other metabolic assets Reiterates focus on TERN-701, a potential best-in-class allosteric BCR-ABL inhibitor, for chronic myeloid leuk...

October 21, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under...

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2025 equity inducement awards to four new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were a...

October 2, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for I...

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025 Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET FOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced it will host an investor educational webinar on TERN-701 in advance of the data re...

August 21, 2025 1 EN
 PRESS RELEASE
Free
TERN Terns Pharmaceu...

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results an...

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates expected in 4Q25 Phase 2 trial of TERN-601 for obesity completed enrollment; 12-week efficacy, safety and tolerability data expected in early 4Q25 Cash runway into 2028 focused on advancing CML program internally and partnering metabolic assets Terns to host a TERN-701-focused educational webinar in September 2025 FOSTER CITY,...

August 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch